4,068 posters, 219 videos, 101 topics, 69 sessions, 14,365 authors, 6,128 institutions
ePostersLive by SciGen Technologies S.A. All rights reserved.
Alzheimer's Association International Conference 2026
July 12-15, 2026 | London, United Kingdom, and Online
1131
Preliminary Analysis Of The Phase 2 Trial For Rapamycin Effects On Alzheimer's Disease And Cognitive Health (REACH)
Poster Presenter
Authors
Valentina R. Garbarino, Rose Ann Barajas, Karl Li, Chen-Pin Wang, Veronica Galvan Hart, Amy Saklad, Monica Goss, Samuel Guess, Lakshmi Cherukuwada, Jessica Zapata, Mayuresh P. Chaudhari, Carlos A. Gaona, Angel G. Velarde, Katherine Guillen, Larissa Werneck, Vinu Phillip, Cynthia Cornejo, Maryam Bahadori, Ashley LaRoche, Vanessa M. Young, Julie M. Parker-Garza, Daniel MacCarthy, Joy Zeynoun, Noor Imran, Floyd A. Jones, Arash Salardini, Jordan Grow, Sidath C. Kumarapperuma, Eduardo Zilli, Gabriel de Erausquin, Sarah E. Savoia, Sara Doyle, Rebecca Hoyumpa, Pavel Rodriguez, Mitzi M. Gonzales, Tiffany F. Kautz, Ellen Kraig, Peter Fox, Dean L. Jr. Kellogg, Sudha Seshadri
Affiliations
Glenn Biggs Institute, The University of Texas Health San Antonio, Center for Geroscience and Healthy Brain Aging, The University of Oklahoma, Cedars-Sinai Medical Center, Los Angeles
Part of Topic
Preliminary results from the first placebo-controlled clinical trial of Rapamycin (Sirolimus®) 1mg daily for 1 year in individuals with early stage Alzheimer’s disease indicate safety, tolerability, and feasibility. Preliminary analyses of pre/post cognitive function, metabolic and blood outcomes indicate early treatment effects do not persist into post-treatment follow-up.
Comments
Email is required but is not shown publicly.
Loading comments...